Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84172 trials found · Page 8 of 4209
-
New 'Living Drug' trial offers hope for patients out of treatment options
Disease control Not yet recruitingThis is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Could breast cancer surgery become optional? new trial tests bold approach
Disease control Not yet recruitingThis clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer patients in complete response after neoadjuvant chemo-i…
Phase: NA • Sponsor: Institut Curie • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Magic mushroom therapy tested for Veterans' depression and addiction
Disease control Not yet recruitingThe goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder (SUD) in veterans and first responders. We seek to ans…
Phase: PHASE1, PHASE2 • Sponsor: Indiana University • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Scientists test 'Living Drug' against Tough-to-Treat abdominal cancer
Disease control Not yet recruitingTo find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 21, 2026 08:34 UTC
-
New hope for leukemia patients: drug boosts transplant success?
Disease control Not yet recruitingThis phase II MyeloMATCH treatment trial compares the effect of adding venetoclax or placebo to reduced intensity conditioning chemotherapy with fludarabine and busulfan or melphalan, with or without total body irradiation, followed by hematopoietic stem cell transplant and eithe…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Spray-On chemo: trial tests direct cancer attack for tough tumors
Disease control Not yet recruitingThis phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leucovorin calcium, fluorouracil, and irinotecan hydrochloride \[FOLFIRI regimen\] plus bevacizumab) in treating patients wit…
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
Double attack on leukemia: new pill teams up with supercharged immune cells
Disease control Not yet recruitingThis phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come back after a period of improvement (relapsed) or that does not respond to treat…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
VA tests 5-Day brain zap treatment for veteran PTSD
Disease control Not yet recruitingVeterans with posttraumatic stress disorder (PTSD) need more effective treatments. Existing options can have limited adherence and can be very time-consuming. As such, alternative interventions are needed. Transcranial magnetic stimulation (TMS) has been FDA-cleared for depressio…
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Apr 15, 2026 16:13 UTC
-
Gene therapy injection tested in Real-World fight against debilitating muscle disease
Disease control Not yet recruitingThe primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Veterans helping veterans: new program aims to stop suicide through shared experience
Prevention Not yet recruitingThis study examines a novel way to prevent suicide among Veterans with serious mental illness (SMI). It will assess the efficacy of PREVAIL-VA, a 3-month intervention of 12, one-on-one sessions between a Peer Specialist (PS) and a Veteran that involve semi-structured conversation…
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Apr 20, 2026 16:15 UTC
-
New push to wipe out lingering leukemia before transplant
Disease control Not yet recruitingThis phase II MyeloMATCH treatment trial compares cytarabine versus (vs.) cytarabine and venetoclax vs. liposome-encapsulated daunorubicin-cytarabine and venetoclax vs. azacitidine and venetoclax for treating patients who have residual disease after treatment for acute myeloid le…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
Hope for rare brain disorder: cannabis extract trial shows promise for devastating childhood condition
Disease control Not yet recruitingThe FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design. RTT is a devastating rare genetic condition affecting females and involves…
Phase: PHASE2, PHASE3 • Sponsor: Fenix Innovation Group • Aim: Disease control
Last updated Apr 21, 2026 08:35 UTC
-
Gene therapy trial aims to free gaucher patients from lifelong treatments
Disease control Not yet recruitingThis study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the effica…
Phase: PHASE3 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New cell therapy trial targets tough pancreatic cancer
Disease control Not yet recruitingThis is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and metastatic pancreatic cancer. The primary objectives are to …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 21, 2026 08:34 UTC
-
New drug combo aims to outsmart aggressive blood cancer
Disease control Not yet recruitingThe purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Im…
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Apr 06, 2026 14:06 UTC
-
New Alzheimer's vaccine trial aims to slow memory loss
Disease control Not yet recruitingThe Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evalu…
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
One-Shot cell therapy aims to reset immune system in severe lupus
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evalu…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
Direct-to-Brain cell therapy tested for deadly recurrent cancer
Disease control Not yet recruitingThis is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) …
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Scientists launch bold attack on rare, deadly 'Mixed' leukemia
Disease control Not yet recruitingAcute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Breakthrough Alzheimer's trial tests multiple new therapies simultaneously
Disease control Not yet recruitingThe goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. …
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC